Another setback for Opdualag's post-melanoma plan
The latest failure, in colorectal cancer, follows a recent disappointment in second-line liver.
Moderna moves on swiftly with its neoantigen immunotherapy
Lung cancer will soon join melanoma as a phase 3 indication for mRNA-4157, an asset Merck & Co last year endorsed to the tune of $250m.
Immatics builds on its PRAME success
PRAME has become a hot target for Immatics, which is now clinically progressing two different modalities against this antigen.
ASCO 2023 – in Lag3 Regeneron could beat Bristol Myers Squibb
Regeneron’s fianlimab could be biopharma’s most potent Lag3 project, and has shown activity in a new melanoma setting
